ROQ Stock Overview
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Roquefort Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.045 |
| 52 Week High | UK£0.095 |
| 52 Week Low | UK£0.038 |
| Beta | -0.088 |
| 1 Month Change | -37.24% |
| 3 Month Change | -32.59% |
| 1 Year Change | -32.59% |
| 3 Year Change | -46.47% |
| 5 Year Change | n/a |
| Change since IPO | -32.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| ROQ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -4.2% | -0.4% | 2.2% |
| 1Y | -32.6% | -29.1% | 0.9% |
Return vs Industry: ROQ underperformed the UK Biotechs industry which returned -29.5% over the past year.
Return vs Market: ROQ underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| ROQ volatility | |
|---|---|
| ROQ Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ROQ's share price has been volatile over the past 3 months.
Volatility Over Time: ROQ's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 9 | Ajan Reginald | www.roquefortinvest.com |
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company’s pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.
Roquefort Therapeutics plc Fundamentals Summary
| ROQ fundamental statistics | |
|---|---|
| Market cap | UK£5.88m |
| Earnings (TTM) | -UK£1.64m |
| Revenue (TTM) | UK£200.00k |
29.4x
P/S Ratio-3.6x
P/E RatioIs ROQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROQ income statement (TTM) | |
|---|---|
| Revenue | UK£200.00k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£200.00k |
| Other Expenses | UK£1.84m |
| Earnings | -UK£1.64m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 100.00% |
| Net Profit Margin | -817.75% |
| Debt/Equity Ratio | 0% |
How did ROQ perform over the long term?
See historical performance and comparison